Content about Prasugrel

August 16, 2011

Study: Effient reduces cardiovascular risk among younger, heavier patient cohort

A special group of patients who participated in a trial of a heart disease drug made by Daiichi Sankyo and Eli Lilly showed fewer heart attacks, strokes and deaths related to cardiovascular disease than patients taking a competing drug, according to an analysis of study results.

INDIANAPOLIS — A special group of patients who participated in a trial of a heart disease drug made by Daiichi Sankyo and Eli Lilly showed fewer heart attacks, strokes and deaths related to cardiovascular disease than patients taking a competing drug, according to an analysis of study results.

December 10, 2009

PricewaterhouseCoopers: Personalized medicine market to grow 11% annually

PricewaterhouseCoopers’ report that the personalized medicine market will grow 11% per year is just another...

NEW YORK PricewaterhouseCoopers’ report that the personalized medicine market will grow 11% per year is just another indication that the field could become the next generation of community pharmacy.